DE602005016729D1 - Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung - Google Patents

Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Info

Publication number
DE602005016729D1
DE602005016729D1 DE602005016729T DE602005016729T DE602005016729D1 DE 602005016729 D1 DE602005016729 D1 DE 602005016729D1 DE 602005016729 T DE602005016729 T DE 602005016729T DE 602005016729 T DE602005016729 T DE 602005016729T DE 602005016729 D1 DE602005016729 D1 DE 602005016729D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
methylthioadenosine
autoimmune diseases
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016729T
Other languages
English (en)
Inventor
Diaz Pablo Villoslada
Zaragoza Matias Avila
Bruna Beatriz Moreno
Izquierdo Fernando Corrales
Lasarte Carmen Berasain
Garcia-Trevijano Elena Ruiz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of DE602005016729D1 publication Critical patent/DE602005016729D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
DE602005016729T 2005-03-17 2005-03-17 Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung Active DE602005016729D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes

Publications (1)

Publication Number Publication Date
DE602005016729D1 true DE602005016729D1 (de) 2009-10-29

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016729T Active DE602005016729D1 (de) 2005-03-17 2005-03-17 Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Country Status (19)

Country Link
US (1) US7820637B2 (de)
EP (1) EP1891961B1 (de)
JP (1) JP2008533107A (de)
CN (1) CN101141970A (de)
AT (1) ATE442854T1 (de)
AU (1) AU2005329287B2 (de)
BR (1) BRPI0520129A2 (de)
CA (1) CA2601557A1 (de)
CY (1) CY1109539T1 (de)
DE (1) DE602005016729D1 (de)
DK (1) DK1891961T3 (de)
ES (1) ES2334924T3 (de)
HR (1) HRP20090646T1 (de)
MX (1) MX2007011327A (de)
PL (1) PL1891961T3 (de)
PT (1) PT1891961E (de)
RS (1) RS51122B (de)
SI (1) SI1891961T1 (de)
WO (1) WO2006097547A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
JP2012529477A (ja) 2009-06-11 2012-11-22 プロイェクト デ ビオメディシーナ シマ，ソシエダー．リミターダ． ５’−メチルチオアデノシンの神経保護特性
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 ＰＰＡＲγ活性化剤
CN105255887B (zh) * 2015-07-17 2018-05-18 四川大学 一种重组慢病毒及其在制备治疗可卡因成瘾的药物中的用途
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
US20220152073A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) * 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp ＴＮＦ−α産生抑制剤および／またはＩＬ−１０産生促進剤
DE60103976T2 (de) * 2000-01-31 2005-07-21 Pfizer Products Inc., Groton Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme
WO2001066518A1 (fr) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. E-ALCOOLS PHENYL-PROSTAGLANDINE φ-SUBSTITUES, PROCEDE DE PREPARATION ASSOCIE ET MEDICAMENTS RENFERMANT CES DERNIERS EN TANT QUE PRINCIPE ACTIF
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
DK1891961T3 (da) 2009-12-21
JP2008533107A (ja) 2008-08-21
PT1891961E (pt) 2009-12-17
CY1109539T1 (el) 2014-08-13
AU2005329287B2 (en) 2011-01-27
MX2007011327A (es) 2008-01-28
PL1891961T3 (pl) 2010-02-26
CA2601557A1 (en) 2006-09-21
EP1891961B1 (de) 2009-09-16
US7820637B2 (en) 2010-10-26
EP1891961A1 (de) 2008-02-27
BRPI0520129A2 (pt) 2009-04-28
AU2005329287A1 (en) 2006-09-21
HRP20090646T1 (hr) 2010-01-31
WO2006097547A1 (es) 2006-09-21
US20090042831A1 (en) 2009-02-12
ES2334924T3 (es) 2010-03-17
CN101141970A (zh) 2008-03-12
ATE442854T1 (de) 2009-10-15
SI1891961T1 (sl) 2010-01-29
RS51122B (sr) 2010-10-31

Similar Documents

Publication Publication Date Title
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
MY144318A (en) Methods of treating hiv infection.
DE60328486D1 (de) Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE602006018725D1 (de) Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
ATE373477T1 (de) Cci-779 zur behandlung von mantelzelllymphom
DE60304678D1 (de) Idraparinux (sanorg 34006) zur behandlung und sekundärprophylaxe von thromboembolien bei patienten mit tiefer venenthrombose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition